The newest generation of GLP-1 drugs are being hailed by some as “miracle drugs” for the treatment of obesity. But GLP-1s are expensive, insurance coverage is limited, and not everyone with obesity can and or wants to take them. In this episode, which is based on Goldman Sachs Research’s latest Top of Mind report, obesity medicine physician Dr. Fatima Cody Stanford and Jonathan Gruber, professor of economics and chairman of the Economics Department at MIT, discuss how large the addressable market for GLP-1s actually is and the implications for US fiscal health.
If you want more insights from Goldman Sachs, make sure to visit GS.com and sign up for Briefings, a weekly newsletter from Goldman Sachs about trends spanning markets, industries, and the global economy.
Building Brands to Help People Live Better: Outdoor Voices and Tata Harper
How Fintech Is Transforming Consumer Finance
The Evolution of the 'Long Good Buy'
Narrowing the Jobs Gap
The Changing Media Landscape: Disrupting Distribution
Emission Control: The Expanding Low Carbon Economy
Brick and Mortal: Retail's Hard Lessons from E-Commerce
Healthcare's Balance Between Science and Commerce
Brexit: After the Vote
The Big Deal about Big Data
Bright Spots in Emerging Markets
Disruption in Deutschland
Whenever, Wherever: The New Model for Retail
Niche No Longer: ESG Investing Goes Mainstream
Mutant Mosquitoes, 'Peak Stuff' and the Shifting Currents of Innovation
Billion Dollar Babies: Virtual Reality and the Shift to Cloud
"Fat and Flat" and the Market Path from Here
The Markets vs. the Economy - Explaining the Disconnect
Market Viewpoints - Gary Cohn on China, Commodities and Tech IPOs
The Digitization of Finance
Create your
podcast in
minutes
It is Free
TED Radio Hour
FT Alphachat
Freakonomics Radio
Odd Lots
Slate Money